These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6851447)

  • 21. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
    Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
    Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lisuride and pergolide in Parkinson's disease.
    Lang AE; Sheehy MP; Quinn NP; Brincat S; Marsden CD; Parkes D
    Adv Neurol; 1983; 37():109-20. PubMed ID: 6858769
    [No Abstract]   [Full Text] [Related]  

  • 23. One year treatment with lisuride delivery pump in Parkinson's disease.
    Ruggieri S; Stocchi F; Carta A; Bragoni M; Agostini C; Barbato L; Agnoli A
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(1-2):173-83. PubMed ID: 2748858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lisuride infusion pump in Parkinson's disease. A report of two cases.
    Gershanik OS; Scipioni O; García S
    J Neural Transm Suppl; 1988; 27():85-90. PubMed ID: 2969955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease].
    Nomoto M; Iwata S; Irifune M; Kaseda S; Osame M; Fukuda T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):81-7. PubMed ID: 9800199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lisuride infusion pump for Parkinson's disease.
    Lancet; 1986 May; 1(8490):1150-1. PubMed ID: 2871399
    [No Abstract]   [Full Text] [Related]  

  • 27. TRH test and the continuous dopaminergic stimulation in complicated Parkinson's disease.
    Lestingi L; Bonifati V; Stocchi F; Antonozzi I; Meco G
    Eur Neurol; 1992; 32(2):65-9. PubMed ID: 1563463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of a low-dose subcutaneous lisuride infusion in Parkinson's disease.
    Hayashi R; Tako K; Makishita H; Koyama J; Yanagisawa N
    Intern Med; 1998 May; 37(5):444-8. PubMed ID: 9652898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous subcutaneous lisuride infusions in Parkinson's disease.
    Critchley PH; Grandas Perez F; Quinn NP; Parkes JD; Marsden CD
    J Neural Transm Suppl; 1988; 27():55-60. PubMed ID: 2969953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies to modify levodopa treatment.
    Widner H
    Adv Neurol; 2003; 91():229-36. PubMed ID: 12442681
    [No Abstract]   [Full Text] [Related]  

  • 31. Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration.
    Stocchi F; Ruggieri S; Antonini A; Baronti F; Brughitta G; Bellantuono P; Bravi D; Agnoli A
    J Neural Transm Suppl; 1988; 27():27-33. PubMed ID: 3165437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lisuride and bromocryptine in L-Dopa stable-responder parkinsonian patients: a comparative, double-blind evaluation of cardiopressor and neurochemical effects.
    Micieli G; Martignoni E; Cavallini A; Pacchetti C; Rossi F; Horowski R; Nappi G
    Funct Neurol; 1996; 11(6):317-25. PubMed ID: 9074912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease.
    Rinne UK
    Neurology; 1989 Mar; 39(3):336-9. PubMed ID: 2927639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
    Müller T; Kuhn W
    Mov Disord; 2009 Jul; 24(9):1339-43. PubMed ID: 19425084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early dopamine agonist therapy in Parkinson's disease.
    Rinne UK
    Mov Disord; 1989; 4 Suppl 1():S86-94. PubMed ID: 2566915
    [No Abstract]   [Full Text] [Related]  

  • 37. Apomorphine and lisuride infusion. A comparative chronic study.
    Stocchi F; Bramante L; Monge A; Viselli F; Baronti F; Stefano E; Ruggieri S
    Adv Neurol; 1993; 60():653-5. PubMed ID: 8420205
    [No Abstract]   [Full Text] [Related]  

  • 38. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
    Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
    Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ropinirole: new preparation. Wait for more convincing data.
    Prescrire Int; 1998 Apr; 7(34):36-8. PubMed ID: 10183378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of efficacy of lisuride hydrogen maleate with increased doses of levodopa in parkinsonian patients.
    Rabey JM; Treves T; Streifler M; Korczyn AD
    Adv Neurol; 1987; 45():569-72. PubMed ID: 3825734
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.